Literature DB >> 19914449

Adeno-associated viral vectors and their redirection to cell-type specific receptors.

Stefan Michelfelder1, Martin Trepel1.   

Abstract

Efficient and specific delivery of genes to the cell type of interest is a crucial issue in gene therapy. Adeno-associated virus (AAV) has gained particular interest as gene vector recently and is therefore the focus of this chapter. Its low frequency of random integration into the genome and the moderate immune response make AAV an attractive platform for vector design. Like in most other vector systems, the tropism of AAV vectors limits their utility for certain tissues especially upon systemic application. This may in part be circumvented by using AAV serotypes with an in vivo gene transduction pattern most closely fitting the needs of the application. Also, the tropism of AAV capsids may be changed by combining parts of the natural serotype diversity. In addition, peptides mediating binding to the cell type of interest can be identified by random phage display library screening and subsequently be introduced into an AAV capsid region critical for receptor binding. Such peptide insertions can abrogate the natural tropism of AAV capsids and result in detargeting from the liver in vivo. In a novel approach, cell type-directed vector capsids can be selected from random peptide libraries displayed on viral capsids or serotype-shuffling libraries in vitro and in vivo for optimized transduction of the cell type or tissue of interest.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19914449     DOI: 10.1016/S0065-2660(09)67002-4

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  54 in total

1.  Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5.

Authors:  Carole E Harbison; Wendy S Weichert; Brittney L Gurda; John A Chiorini; Mavis Agbandje-McKenna; Colin R Parrish
Journal:  J Gen Virol       Date:  2011-11-09       Impact factor: 3.891

Review 2.  Cocaine hydrolase gene therapy for cocaine abuse.

Authors:  Stephen Brimijoin; Yang Gao
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 3.  Gene therapy for radioprotection.

Authors:  W H Everett; D T Curiel
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

Review 4.  The AAV vector toolkit: poised at the clinical crossroads.

Authors:  Aravind Asokan; David V Schaffer; R Jude Samulski
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

Review 5.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 6.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

Review 7.  Adeno-associated viral vectors for mapping, monitoring, and manipulating neural circuits.

Authors:  J Nicholas Betley; Scott M Sternson
Journal:  Hum Gene Ther       Date:  2011-04-06       Impact factor: 5.695

8.  Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer.

Authors:  Nagesh Pulicherla; Shen Shen; Swati Yadav; Kari Debbink; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Aravind Asokan
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

Review 9.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

10.  Treatment of multifocal breast cancer by systemic delivery of dual-targeted adeno-associated viral vectors.

Authors:  M Trepel; J Körbelin; E Spies; M B Heckmann; A Hunger; B Fehse; H A Katus; J A Kleinschmidt; O J Müller; S Michelfelder
Journal:  Gene Ther       Date:  2015-06-02       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.